Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Singapore
  4. Singapore Stock Exchange
  5. IX Biopharma Ltd.
  6. News
  7. Summary
    42C   SG1BD9000009

IX BIOPHARMA LTD.

(42C)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Singapore Shares Close Higher on Monday; iX Biopharma Rise 2% on Spin off Plans

07/12/2021 | 05:32am EDT


ę MT Newswires 2021
All news about IX BIOPHARMA LTD.
08/24Singapore Shares Close Higher; Singapore Myanmar Soars 8% on Cryptocurrency Mining Mach..
MT
08/24IX BIOPHARMA : Trims FY21 Loss Amid Robust Product Demand in China
MT
08/23Ix Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/23IX BIOPHARMA : 2H (Unaudited)
PU
07/27IX BIOPHARMA : to Supply Medicinal Cannabis Wafers in New Zealand
MT
07/25IX BIOPHARMA : Specialty Pharmaceutical Company iX Biopharma Closes Oversubscribed Rights ..
MT
07/18IX BIOPHARMA : Grants 3 Million Share Options to Employee
MT
07/16EMPLOYEE STOCK OPTION/ SHARE SCHEME : :GRANT OF SHARE OPTION PURSUANT TO iX EMPLOYEE SHARE..
PU
07/12Singapore Shares Close Higher on Monday; iX Biopharma Rise 2% on Spin off Plans
MT
07/11IX Biopharma to Spin off, List Pharmaceutical Business in Hong Kong
MT
More news
Financials
Sales 2021 1,64 M 1,21 M 1,21 M
Net income 2021 -8,90 M -6,57 M -6,57 M
Net Debt 2021 - - -
P/E ratio 2021 -17,7x
Yield 2021 -
Capitalization 172 M 127 M 127 M
Capi. / Sales 2021 105x
Capi. / Sales 2022 13,4x
Nbr of Employees 45
Free-Float 51,1%
Chart IX BIOPHARMA LTD.
Duration : Period :
iX Biopharma Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IX BIOPHARMA LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,23 SGD
Average target price 0,45 SGD
Spread / Average Target 93,5%
EPS Revisions
Managers and Directors
Yip Hang Lee Executive Chairman & Chief Executive Officer
Sien Lup Chew Chief Financial Officer
Iain Bruce Cook Chief Scientist
Janakan Krishnarajah Chief Operating & Chief Medical Officer
Weng Keong Low Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IX BIOPHARMA LTD.-9.80%127
JOHNSON & JOHNSON3.68%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY34.09%210 037